Amarin reported $-1.22M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 3.61B 2.92B Jun/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amarin USD -1.22M 6.51M Dec/2025
AstraZeneca USD 2.51B 573M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
DBV Technologies USD -47.6M 2.77M Mar/2026
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Novartis USD 3.26B 108M Jun/2026